PubRank

Guido Reifenberger

Author PubWeight™ 263.80‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 International network of cancer genome projects. Nature 2010 20.35
2 Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 2012 10.99
3 The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002 8.62
4 Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009 7.73
5 Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012 6.71
6 Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012 6.20
7 Dissecting the genomic complexity underlying medulloblastoma. Nature 2012 4.77
8 Long-term survival with glioblastoma multiforme. Brain 2007 4.51
9 NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009 4.32
10 IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature 2012 4.04
11 BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008 3.98
12 Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma. J Nucl Med 2012 3.67
13 Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011 3.66
14 Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 2009 3.65
15 MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nat Rev Neurol 2009 3.32
16 International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol 2014 3.21
17 Histological classification and molecular genetics of meningiomas. Lancet Neurol 2006 3.19
18 Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. Cancer Res 2007 3.05
19 Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol 2009 3.01
20 Temozolomide preferentially depletes cancer stem cells in glioblastoma. Cancer Res 2008 2.84
21 Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010 2.71
22 Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol 2009 2.67
23 A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010 2.49
24 Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013 2.42
25 Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 2003 2.38
26 O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005 2.37
27 EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 2013 2.28
28 Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012 2.17
29 Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007 2.11
30 Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 2013 1.98
31 Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol 2005 1.83
32 Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 2008 1.74
33 Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro Oncol 2012 1.68
34 Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Int J Cancer 2007 1.67
35 Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system. Acta Neuropathol 2010 1.65
36 Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 2010 1.65
37 Integrative genomic analysis identifies NDRG2 as a candidate tumor suppressor gene frequently inactivated in clinically aggressive meningioma. Cancer Res 2005 1.63
38 Pten signaling in gliomas. Neuro Oncol 2002 1.62
39 Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res 2009 1.61
40 Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer 2011 1.61
41 Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 2003 1.57
42 Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol 2004 1.55
43 Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol 2013 1.50
44 Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas. Int J Cancer 2004 1.50
45 Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005 1.48
46 Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 2009 1.46
47 The nuclear receptor tailless induces long-term neural stem cell expansion and brain tumor initiation. Genes Dev 2010 1.45
48 ECRG4 is a candidate tumor suppressor gene frequently hypermethylated in colorectal carcinoma and glioma. BMC Cancer 2009 1.44
49 Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 2006 1.43
50 Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. Acta Neuropathol 2014 1.42
51 Molecular pathogenesis of meningiomas. J Neurooncol 2004 1.42
52 Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007 1.42
53 Troglitazone-mediated sensitization to TRAIL-induced apoptosis is regulated by proteasome-dependent degradation of FLIP and ERK1/2-dependent phosphorylation of BAD. Cancer Biol Ther 2008 1.41
54 Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 2003 1.41
55 Molecular diagnostics of gliomas: state of the art. Acta Neuropathol 2010 1.40
56 Genotype and protein expression after bone marrow transplantation for adrenoleukodystrophy. Arch Neurol 2007 1.38
57 Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 2013 1.37
58 Microarray-based gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated with meningioma progression. Int J Cancer 2005 1.36
59 Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 2015 1.35
60 Frequent promoter hypermethylation and transcriptional downregulation of the NDRG2 gene at 14q11.2 in primary glioblastoma. Int J Cancer 2008 1.33
61 Comparative pathology of nerve sheath tumors in mouse models and humans. Cancer Res 2004 1.31
62 Frequent promoter hypermethylation of Wnt pathway inhibitor genes in malignant astrocytic gliomas. Int J Cancer 2010 1.31
63 Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 2009 1.30
64 Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 2002 1.29
65 Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 2004 1.29
66 Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 2011 1.27
67 Diagnosis of pseudoprogression in patients with glioblastoma using O-(2-[18F]fluoroethyl)-L-tyrosine PET. Eur J Nucl Med Mol Imaging 2014 1.26
68 Refined mapping of 1q32 amplicons in malignant gliomas confirms MDM4 as the main amplification target. Int J Cancer 2003 1.23
69 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med 2006 1.22
70 Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res 2009 1.19
71 Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations. Clin Cancer Res 2013 1.17
72 Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 2015 1.16
73 Prospective cohort study of radiotherapy with concomitant and adjuvant temozolomide chemotherapy for glioblastoma patients with no or minimal residual enhancing tumor load after surgery. J Neurooncol 2012 1.15
74 Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res 2010 1.15
75 Molecular genetic analysis of malignant melanomas for aberrations of the WNT signaling pathway genes CTNNB1, APC, ICAT and BTRC. Int J Cancer 2002 1.11
76 Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS One 2007 1.11
77 The Wnt secretion protein Evi/Gpr177 promotes glioma tumourigenesis. EMBO Mol Med 2011 1.10
78 Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells. J Neurochem 2012 1.09
79 Hypermethylation and transcriptional downregulation of the carboxyl-terminal modulator protein gene in glioblastomas. J Natl Cancer Inst 2004 1.09
80 Molecular signatures classify astrocytic gliomas by IDH1 mutation status. Int J Cancer 2011 1.08
81 Role of LIM and SH3 protein 1 (LASP1) in the metastatic dissemination of medulloblastoma. Cancer Res 2010 1.07
82 Expression of Bcl-2 family member Bid in normal and malignant tissues. Neoplasia 2002 1.07
83 Comparison of (18)F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging 2010 1.06
84 5-aminolevulinic acid (5-ALA)-induced fluorescence in intracerebral metastases: a retrospective study. Acta Neurochir (Wien) 2011 1.06
85 Gliomatosis cerebri: molecular pathology and clinical course. Ann Neurol 2002 1.06
86 Multimodal metabolic imaging of cerebral gliomas: positron emission tomography with [18F]fluoroethyl-L-tyrosine and magnetic resonance spectroscopy. J Neurosurg 2005 1.05
87 MiR-328 promotes glioma cell invasion via SFRP1-dependent Wnt-signaling activation. Neuro Oncol 2013 1.04
88 Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 2007 1.03
89 Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathol 2014 1.01
90 Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015 0.99
91 Molecular genetic analysis of central nervous system germ cell tumors with comparative genomic hybridization. Mod Pathol 2006 0.99
92 Fatal glioblastoma multiforme in a patient with neurofibromatosis type I: the dilemma of systematic medical follow-up. Childs Nerv Syst 2006 0.98
93 Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3. Cancer Res 2004 0.98
94 MGMT promoter methylation in malignant gliomas. Target Oncol 2010 0.97
95 Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer 2006 0.97
96 Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathol 2015 0.97
97 Role of O-(2-18F-fluoroethyl)-L-tyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma. J Nucl Med 2013 0.95
98 Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol 2013 0.95
99 SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathol 2011 0.95
100 Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer 2014 0.95
101 Differential retinoic acid signaling in tumors of long- and short-term glioblastoma survivors. J Natl Cancer Inst 2011 0.94
102 Interferon-β induces loss of spherogenicity and overcomes therapy resistance of glioblastoma stem cells. Mol Cancer Ther 2014 0.94
103 Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 2010 0.93
104 Identification of genomic aberrations associated with shorter overall survival in patients with oligodendroglial tumors. Int J Cancer 2007 0.93
105 Identification of novel genes associated with astrocytoma progression using suppression subtractive hybridization and real-time reverse transcription-polymerase chain reaction. Int J Cancer 2006 0.92
106 DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas. Brain Pathol 2007 0.91
107 Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status. J Neurooncol 2009 0.91
108 Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas. Acta Neuropathol 2004 0.91
109 Association of stem cell-related markers and survival in astrocytic gliomas. Biomarkers 2011 0.91
110 Genetic alterations commonly found in diffusely infiltrating cerebral gliomas are rare or absent in pleomorphic xanthoastrocytomas. J Neuropathol Exp Neurol 2002 0.90
111 Inflammatory demyelinating brain lesions heralding primary CNS lymphoma. Can J Neurol Sci 2012 0.90
112 A 21-year-old female with a third ventricular tumor. Brain Pathol 2006 0.90
113 Unraveling the glioma epigenome: from molecular mechanisms to novel biomarkers and therapeutic targets. Brain Pathol 2011 0.90
114 Nos2 inactivation promotes the development of medulloblastoma in Ptch1(+/-) mice by deregulation of Gap43-dependent granule cell precursor migration. PLoS Genet 2012 0.89
115 Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol 2007 0.89
116 Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain 2013 0.89
117 Can the apparent diffusion coefficient be used as a noninvasive parameter to distinguish tumor tissue from peritumoral tissue in cerebral gliomas? J Magn Reson Imaging 2004 0.88
118 Haplotype-specific expression of the human PDGFRA gene correlates with the risk of glioblastomas. Int J Cancer 2008 0.88
119 Aberrant expression of retinoic acid signaling molecules influences patient survival in astrocytic gliomas. Am J Pathol 2011 0.88
120 Molecular classification of human gliomas using matrix-based comparative genomic hybridization. Int J Cancer 2005 0.88
121 Hypermethylation and transcriptional downregulation of the TIMP3 gene is associated with allelic loss on 22q12.3 and malignancy in meningiomas. Brain Pathol 2009 0.88
122 Astrocytic tumors. Recent Results Cancer Res 2009 0.87
123 Giant cell glioblastoma is associated with altered aurora b expression and concomitant p53 mutation. J Neuropathol Exp Neurol 2010 0.87
124 Long-term control of disseminated pleomorphic xanthoastrocytoma with anaplastic features by means of stereotactic irradiation. Neuro Oncol 2009 0.86
125 Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathol 2007 0.86
126 Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia. Nucl Med Biol 2006 0.85
127 Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. Int J Cancer 2008 0.85
128 Glioblastoma with adipocyte-like tumor cell differentiation--histological and molecular features of a rare differentiation pattern. Brain Pathol 2008 0.85
129 Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild-type glioblastoma. Genes Chromosomes Cancer 2014 0.83
130 NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 2011 0.83
131 Molecular neuropathology of gliomas. Int J Mol Sci 2009 0.83
132 RANK (TNFRSF11A) is epigenetically inactivated and induces apoptosis in gliomas. Neoplasia 2012 0.83
133 Absence of mutations in the putative tumor suppressor gene KLF6 in glioblastomas and meningiomas. Int J Cancer 2004 0.82
134 Comparison of O-(2-18F-fluoroethyl)-L-tyrosine and L-3H-methionine uptake in cerebral hematomas. J Nucl Med 2010 0.82
135 Allelic gain and amplification on the long arm of chromosome 17 in anaplastic meningiomas. Brain Pathol 2002 0.82
136 5-ALA-induced fluorescence behavior of reactive tissue changes following glioblastoma treatment with radiation and chemotherapy. Acta Neurochir (Wien) 2014 0.81
137 Absence of immunoglobulin class switch in primary lymphomas of the central nervous system. Am J Pathol 2005 0.81
138 Simultaneous extraction of nucleic acids and proteins from tissue specimens by ultracentrifugation: A protocol using the high-salt protein fraction for quantitative proteome analysis. Proteomics 2009 0.81
139 Element distribution is altered in a zone surrounding human glioblastoma multiforme. J Trace Elem Med Biol 2007 0.81
140 Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. Curr Opin Oncol 2016 0.81
141 Neurotransmitter receptor imbalances in motor cortex and basal ganglia in hepatic encephalopathy. Cell Physiol Biochem 2009 0.80
142 Genetic and expression profiles of cerebellar liponeurocytomas. Brain Pathol 2004 0.80
143 Potential canonical wnt pathway activation in high-grade astrocytomas. ScientificWorldJournal 2012 0.80
144 Expression of nuclear receptor corepressors and class I histone deacetylases in astrocytic gliomas. Cancer Sci 2010 0.79
145 How stemlike are sphere cultures from long-term cancer cell lines? Lessons from mouse glioma models. J Neuropathol Exp Neurol 2014 0.79
146 DNA hypermethylation and histone modifications downregulate the candidate tumor suppressor gene RRP22 on 22q12 in human gliomas. Brain Pathol 2011 0.79
147 Whole-genome paired-end analysis confirms remarkable genomic stability of atypical teratoid/rhabdoid tumors. Genes Chromosomes Cancer 2013 0.78
148 Novel insights into the pathogenesis of gliomas based on large-scale molecular profiling approaches. Curr Opin Neurol 2009 0.78
149 Tumor-free survival of 7 years after gene therapy for recurrent glioblastoma. Neurology 2003 0.77
150 Influencing the Wnt signaling pathway in multiple myeloma. Anticancer Res 2011 0.77
151 Detection of secondary thalamic degeneration after cortical infarction using cis-4-18F-fluoro-D-proline. J Nucl Med 2007 0.77
152 Assessing quality and functionality of DNA isolated from FFPE tissues through external quality assessment in tissue banks. Clin Chem Lab Med 2015 0.77
153 Differential proteome analysis of human gliomas stratified for loss of heterozygosity on chromosomal arms 1p and 19q. Neuro Oncol 2010 0.76
154 Molecular diagnostics of brain tumors. Acta Neuropathol 2010 0.76
155 Absence of detectable alterations in the putative tumor suppressor gene BTRC in cerebellar medulloblastomas and cutaneous basal cell carcinomas. Acta Neuropathol 2003 0.76
156 Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 2016 0.75
157 Rosetted glioneuronal tumor of the spine with overtly anaplastic histological features. Acta Neuropathol 2009 0.75
158 Reply: discriminating ability of (18)F-FET PET for several cerebral neoplastic lesions. J Nucl Med 2013 0.75
159 Prostate adenocarcinoma metastasis in the pituitary gland. Arch Neurol 2009 0.75
160 Diffuse leptomeningeal astrocytoma in a patient with infantile epilepsy. Arch Neurol 2009 0.75
161 Intradural, extramedullary anaplastic astrocytoma arising from the first sacral nerve root. JAMA Neurol 2013 0.75